Spyre Therapeutics (SYRE) Operating Income (2016 - 2025)
Historic Operating Income for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to -$56.9 million.
- Spyre Therapeutics' Operating Income fell 270.08% to -$56.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.6 million, marking a year-over-year decrease of 1056.58%. This contributed to the annual value of -$208.6 million for FY2024, which is 1392.35% up from last year.
- Latest data reveals that Spyre Therapeutics reported Operating Income of -$56.9 million as of Q3 2025, which was down 270.08% from -$41.9 million recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Operating Income ranged from a high of -$6.7 million in Q2 2021 and a low of -$159.2 million during Q2 2023
- Over the past 5 years, Spyre Therapeutics' median Operating Income value was -$24.4 million (recorded in 2022), while the average stood at -$39.7 million.
- As far as peak fluctuations go, Spyre Therapeutics' Operating Income tumbled by 61019.04% in 2023, and later soared by 7227.75% in 2024.
- Spyre Therapeutics' Operating Income (Quarter) stood at -$20.4 million in 2021, then rose by 6.26% to -$19.2 million in 2022, then tumbled by 139.61% to -$45.9 million in 2023, then crashed by 33.41% to -$61.3 million in 2024, then rose by 7.13% to -$56.9 million in 2025.
- Its Operating Income stands at -$56.9 million for Q3 2025, versus -$41.9 million for Q2 2025 and -$53.6 million for Q1 2025.